FTI Consulting, a life science and healthcare communications practice, has named Andrew Ward as its new managing director, it was reported on Friday.
Ward joins the group from the Financial Times, where he was the pharmaceuticals correspondent for almost three years, covering the business, finance, science and regulation of the global pharmaceuticals and medical equipment industries. In the new role, Ward will be expected to broaden and deepen FTI Consulting's client base globally.
Ben Atwell, senior managing director and global head of life sciences and healthcare at FTI Consulting, said: "Andrew was one of the sector's most respected reporters during his time covering healthcare, and brings invaluable global perspective to our prestigious client base. We look forward to benefiting from his deep media experience and welcoming him to our global team of over 50 healthcare experts."
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'